CLINICAL TRIALS PROFILE FOR FIBRINOGEN (HUMAN)

All Clinical Trials for fibrinogen (human)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.
NCT00000466 ↗	Postmenopausal Estrogen/Progestin Interventions (PEPI)	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3	1987-09-01	To assess the effects of various postmenopausal estrogen replacement therapies on selected cardiovascular risk factors, including high density lipoprotein cholesterol, systolic blood pressure, fibrinogen, and insulin and on osteoporosis risk factors. Conducted in collaboration with the National Institute of Child Health and Human Development, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, The National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute on Aging. The extended follow-up is for 3 years focusing on endometrium and breast evaluation.

Clinical Trial Conditions for fibrinogen (human)

Condition Name

Condition Name for fibrinogen (human)
Intervention	Trials
Bleeding	10
Trauma	8
Cardiovascular Diseases	7

Condition MeSH

Condition MeSH for fibrinogen (human)
Intervention	Trials
Hemorrhage	41
Blood Coagulation Disorders	20
Hemostatic Disorders	20

Clinical Trial Locations for fibrinogen (human)

Trials by Country

Trials by Country for fibrinogen (human)
Location	Trials
United States	121
Canada	26
Italy	16
France	15
Indonesia	13

Trials by US State

Trials by US State for fibrinogen (human)
Location	Trials
Maryland	9
Pennsylvania	8
Massachusetts	7
New York	7
Florida	7

Clinical Trial Progress for fibrinogen (human)

Clinical Trial Phase

Clinical Trial Phase for fibrinogen (human)
Clinical Trial Phase	Trials
Phase 4	77
Phase 3	47
Phase 2/Phase 3	13

Clinical Trial Status

Clinical Trial Status for fibrinogen (human)
Clinical Trial Phase	Trials
Completed	126
Recruiting	38
Unknown status	29

Clinical Trial Sponsors for fibrinogen (human)

Sponsor Name

Sponsor Name for fibrinogen (human)
Sponsor	Trials
CSL Behring	8
University of Sao Paulo	6
Supergene, LLC	4

Sponsor Type

Sponsor Type for fibrinogen (human)
Sponsor	Trials
Other	396
Industry	70
NIH	14